SEARCH

SEARCH BY CITATION

Keywords:

  • immunochemotherapy;
  • human immunodeficiency virus;
  • Burkitt's lymphoma or leukemia;
  • prognostic factors

Abstract

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES

BACKGROUND:

The use of rituximab together with intensive chemotherapy in Burkitt's lymphoma or leukemia (BL) has been scarcely explored. This study prospectively evaluated and compared the outcome and toxicity of human immunodeficiency virus (HIV)-positive and HIV-negative patients with BL who were treated in an intensive immunochemotherapy-based and age-adapted trial.

METHODS:

A total of 118 adult patients (80 HIV-negative and 38 HIV-positive) aged 15 to 83 years were treated with 4 (nonbulky stages I-II) or 6 (stages II bulky, III-IV) cycles of intensive chemotherapy combined with rituximab. Reduction in chemotherapy doses and modification of the cycle schedules was performed in patients older than 55 years.

RESULTS:

The clinical characteristics of HIV-positive patients were comparable with those who were HIV-negative. Complete remission rates were 82% and 87%, respectively, and 9 patients died in induction, 9 died in remission, and 7 relapsed. After a median follow-up of 2.5 years, nonsignificant differences were observed in the 4-year disease-free survival and overall survival (OS) probabilities (77% and 63% for HIV-positive and 80% and 78% for HIV-negative patients, respectively). Young HIV-infected patients presented higher incidences of grade 3 or 4 mucositis and severe infectious episodes. Poor general status and bone marrow involvement, but not advanced age, were associated with a shorter OS, allowing the definition of 3 prognostic groups, with the OS ranging from 50% to 92%.

CONCLUSIONS:

Age-adapted intensive immunochemotherapy is highly effective in both HIV-negative and HIV-positive patients, with a higher toxicity in the latter group. Poor general status and bone marrow involvement had a negative impact on survival. Cancer 2013. © 2013 American Cancer Society.


INTRODUCTION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES

Burkitt's lymphoma or leukemia (BL) is a highly aggressive mature B-cell non-Hodgkin's lymphoma, with high incidence in immunosuppressed patients in Western countries, especially when associated with human immunodeficiency virus (HIV) infection.1 The standard treatment consists of specific regimens incorporating intensive courses of chemotherapy with fractionated alkylating agents and phase-specific agents capable of crossing the blood–brain barrier. Intensive chemotherapy regimens have improved the outcome in both children and adults.2 Some uncontrolled studies suggest that the addition of rituximab is efficacious and may be particularly valuable in adult patients.3

In HIV-associated lymphomas, the use of highly active antiretroviral therapy (HAART) has led to an improved tolerance to full-dose chemotherapy. However, the outcomes for HIV-infected patients have only been occasionally compared with those from HIV-negative patients receiving the same chemotherapeutic protocols.4 The addition of rituximab has proven to be effective in aggressive lymphomas arising in HIV-infected patients.5

In the Spanish PETHEMA (Programa Español de Tratamiento en Hematología) cooperative group, patients with BL have been routinely treated with specific regimens irrespective of HIV status.6 In July 2003, a trial adding rituximab to a specific regimen for BL (the BURKIMAB trial) was activated. A report of the first 36 patients (17 HIV-negative and 19 HIV-infected) in advanced stages showed the feasibility of the inclusion of HIV-infected patients, with similar outcome.7 We report the final analysis of this trial, including a study of prognostic factors.

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES

Eligibility and Diagnostic Criteria

The PETHEMA Group adapted the study B-ALL/NHL2002 (ClinicalTrials.gov identifier NCT00199082) from the GMALL (German Multicenter Study Group for the Treatment of Adult Acute Lymphoblastic Leukemia) for the treatment of BL. The main modification in the Spanish study (BURKIMAB, ClinicalTrials.gov identifier NCT00388193) was the inclusion of patients with HIV-related BL. Accrual began in July 2003 for HIV-negative patients and in September 2004 for HIV-positive individuals, and the study was closed for inclusion in July 2011 and for follow-up in December 2011.

Inclusion criteria were age higher than 15 years and BL confirmed by morphology, immunological markers (including CD20 positivity), and cytogenetics. HIV-infected patients had to be under or had to begin HAART. The study was approved by the institutional research boards of the PETHEMA Group and of each center. Informed consent was obtained from all patients.

Diagnosis of BLL was performed according to the Revised European-American Classification of Lymphoid Neoplasms (REAL/WHO) criteria,8 and cases were reclassified according to the World Health Organization Classification9 after review of pathologic reports. Bone marrow (BM) involvement was assessed by aspiration or biopsy (in case of absence of infiltration by BM aspiration). Cytogenetic studies were performed in each center using direct methods and unstimulated short-term (24 and 48 hours) cultures with G-banding,10 and the reports were centrally reviewed. Burkitt's leukemia was defined as > 20% Burkitt's cells in BM. Central nervous system (CNS) disease was defined as cerebrospinal fluid (CSF) involvement by Burkitt's cells, cranial nerve palsy not related to a facial tumor, clinical signs of spinal cord compression, or an intracranial mass.

Parameters Evaluated

The following data were analyzed at baseline: general status (Eastern Cooperative Oncology Group score); the main hematologic and biochemical tests; computed tomography (CT) scan of the chest, abdomen, and pelvis; BM study; CSF study; and age-adjusted International Prognostic Index (aaIPI).11 Bulky disease was defined as a tumor mass > 10 cm in diameter. In HIV-infected patients, HIV viral load and CD4 lymphocyte counts were also recorded.

After therapy, the following evaluations were performed: physical examination, hematologic and biochemical parameters, BM study (if positive at diagnosis), and CT scans of the involved areas at baseline, in addition to CD4 count and viral load of HIV for HIV-infected patients. Response was evaluated after 2 therapy cycles and at the end of the fourth or sixth cycles for patients in localized or advanced stages, respectively. Patients in complete response (CR) were evaluated every 3 months during the first year, every 6 months during the second year, and annually thereafter.

Chemotherapy Regimen

Table 1 shows the therapy of the patients. Patients in advanced stage (bulky stages II or stages III-IV) and younger than 55 years received 2 courses of cycles A, B, and C, whereas older patients received 3 courses of alternating cycles A and B, for a total of 6 cycles. Patients with localized stage (nonbulky stages I-II) received 4 cycles of treatment. Reduction of 50% in methotrexate and cytarabine doses was performed in patients older than 55 years. A single dose of rituximab was administered before each cycle. After completion of chemotherapy, those patients in advanced stages who experienced CR received 2 additional doses of rituximab. CNS prophylaxis consisted of 8 doses of triple intrathecal therapy (TIT). CNS-directed therapy included TIT chemotherapy twice weekly until normalization of the cytologic study of CSF. Once they achieved a negative CSF status, patients followed the prophylactic scheme described above.

Table 1. Protocol Treatmenta
Cycle/DayDrugDose (mg/m2)Route
  • a

    Cycles A to C are repeated from days 77 to 124 to complete 6 treatment cycles after the prephase. After completion of the treatment, 2 additional doses of rituximab were given (weeks 21 and 24) for a total of 8 doses of rituximab.

  • b

    Folinic acid rescue from 12 hours after the end of infusion.

  • c

    One-half to one-third in patients over 55 years of age.

  • Abbreviation: IV, intravenous.

Prephase
1-5Cyclophosphamide200IV (1h)
1-5Prednisone60IV bolus
Cycle A
7Rituximab375IV (4h)
8Vincristine2 mg (absolute)IV bolus
8Methotrexate1500IV (24h)b,c
8-12Iphosphamide800IV (1h)
8-12Dexamethasone10IV bolus
11-12Teniposide (VM26)100IV (1h)
11-12Cytarabine150IV (1h)/12h
Cycle B
28Rituximab375IV (4h)
29Vincristine2 mg (absolute)IV bolus
29Methotrexate1500IV (24h)
29-33Cyclophosphamide200IV (1h)
29-33Dexamethasone10IV bolus
32-33Doxorubicin25IV (15min)
Cycle C
49Rituximab375IV (4h)
50Vindesine3 (maximum 5 mg)IV bolus
50Methotrexate1500IV (24h)b
50-54Dexamethasone10IV bolus
53-54Etoposide (VP16)250IV (1h)
54Cytarabine2000IV (3h)/12h
Central nervous system prophylaxis
1-8-12-29-33Methotrexate15 mgintrathecal
Cytarabine40 mg 
Dexamethasone20 mg 

Supportive Care and Complementary Treatment

Intravenous hydration, rasburicase use, and general supportive measures were not prescribed by the protocol. The dose of methotrexate was reduced to 0.5 g/m2 in patients with levels of creatinine > 2 mg/dL or bilirubin > 2 mg/dL, and 25% to 50% of dose reduction of methotrexate, cytarabine, and vincristine were recommended if severe mucositis, liver toxicity, or severe neurotoxicity occurred in previous cycles.

HAART was not uniform in all patients, but should include 1 protease inhibitor or a non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitors, and was started at BLL diagnosis in HIV-infected patients who did not previously receive it. Pneumocystis jiroveci prophylaxis was scheduled for HIV-infected patients who had a CD4 cell count below 200/μL at baseline. Granulocyte colony-stimulating factor was allowed for use from neutrophils < 0.5 × 109/L until recovery for each cycle.

Response Criteria, Outcome Measures, and Evaluation of Toxicity

Complete response was defined as disappearance of extramedullary disease, as determined by physical examination and imaging studies after 2 cycles. In cases of Burkitt's leukemia, a normocellular marrow with < 5% blasts and recovery of peripheral blood counts was required. Partial remission (PR) was defined as > 50% reduction of all measurable lesions. Progressive disease (PD) was considered when > 25% increase in the size of lesions was documented. Both PR and PD were considered as treatment failures.

Early death (ED) was defined as death within 8 weeks of therapy onset (before first response evaluation). Treatment failure was defined when a patient did not reach PR after the first 2 cycles or CR after 4. Relapse was defined as disease recurrence at any site after at least 2 months of documented CR. Overall survival (OS) was calculated from the date of diagnosis to death or to the last follow-up. Disease-free survival (DFS) was defined as the time interval between CR and relapse, death due to any cause, or to the date of the last follow-up.

Toxicity was evaluated according to National Cancer Institute (NCI) Common Toxicity Criteria, version 3.0.

Statistical Methods

Toxicity, response to therapy, and prognostic factors for ED, CR, OS, and DFS were the main variables under study. Chi-square test, Fisher's exact test, Student t test, or Kruskal-Wallis test were used for comparisons of baseline characteristics and for comparisons among study groups. Prognostic factors associated with early death and CR were calculated using the Student t test or chi-square test when appropriate. In the multivariate analysis, odds ratios and the 95% confidence intervals (95% CIs) were calculated by logistic regression analysis. Survival curves were plotted according to the Kaplan-Meier method12 and were compared by the log-rank test.13 The Cox proportional hazard ratio model was used for univariate and multivariate survival analyses.14

RESULTS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES

Patients

A total of 140 patients were registered at 23 Spanish centers, of whom 118 were valid for this study. Twenty-two patients (16%) were excluded because they fulfilled the WHO criteria for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma9 after review of the pathologic reports. Table 2 shows the characteristics of the118 valid patients (80 HIV-negative and 38 HIV-positive).The cohorts of HIV-positive and HIV-negative patients were comparable for the main clinical and biological parameters at diagnosis. There was a trend to a lower frequency of Burkitt's leukemia in HIV-infected patients. In HIV-positive patients, the CD4 lymphocyte count waslower than 200/μL in 21 of 37 cases (57%) (median = 194/μL; range = 20-1180/μL), HIV viral load was detectable in 28 of 37 patients (76%), and BLL led to the diagnosis of HIV infection in 4 patients (11%).

Table 2. Baseline Characteristics of the 118 Patients According to Human Immunodeficiency Virus Infection Status
CharacteristicHIV-Infected (n = 38)Non-HIV-Infected (n = 80)All (n = 118)P
  1. Abbreviations: CNS, central nervous system; ECOG:Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; IPI, International Prognostic Index; LDH, lactate dehydrogenase.

Sex, male n (%)31 (82%)54 (68%)85 (72%).129
Age, median (minimum; maximum)42 (20; 58)47 (15; 83)44 (5; 83).111
Diagnosis, n (%)Burkitt lymphoma34 (90%)59 (74%)93 (79%).057
Burkitt leukemia4 (10%)21 (26%)25 (21%)
Stage, n (%)Non-bulky I-II5 (13%)21 (26%)26 (22%).154
II(bulky), III-IV33 (87%)59 (74%)92 (78%)
ECOG ≥2, n (%)21 (55%)34/79 (43%)55 (47%).240
Extranodal involvement (≥2 sites), n (%)17 (45%)38 (48%)55 (47%).845
CNS involvement, n(%)3 (8%)11 (14%)14 (12%).544
Bulky disease, n(%)14 (37%)17 (21%)31 (26%).079
LDH level above normal, n(%)37 (97%)69/78 (89%)106/116 (91%).162
Age-adjusted IPI, n (%)Low1 (3%)5/78 (6%)6/116 (5%).203
Low-intermediate3 (8%)14/78 (18%)17/116 (15%)
Intermediate-high14 (37%)32/78 (41%)46/116 (40%)
High20 (52%)27/78 (35%)47/116 (40%)

Response to Treatment and Survival

Table 3 shows the main outcomes of the whole series and of the HIV-positive and HIV-negative patients. Although no statistically significant differences in any response parameter were observed between HIV-positive and HIV-negative patients, it is notable that ED was more frequent in HIV-infected patients. Infection was the cause of all early deaths.

Table 3. Treatment Outcome for the Overall Group and According to Human Immunodeficiency Virus Infection Status
VariableHIV-InfectedNon-HIV-InfectedAll
  • a

    Systemic fungal infection (n = 3, Scedosporium prolificans, Geotrichum capitatum, and Candida glabrata), septic shock (n = 4), and bilateral pneumonia (n = 2).

  • b

    Aspergillus spp. (n = 2), Candida albicans (n = 1), gram-negative sepsis (n = 4, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa [n = 2]), central nervous system hemorrhage (n = 1), pneumonia (n = 1).

  • c

    A total of 6 patients died in C1, 1 patient in A2, 1 patient in B2, and 1 patient in C2.

  • Abbreviation: HIV, human immunodeficiency virus.

Evaluable patients3880118
Early withdrawal2 (3%)2 (2%)
Death in induction5 (13%)4 (5%)9 (8%)a
Failure2 (5%)4 (5%)6 (5%)
Complete response31 (82%)70 (87%)101 (85%)
Relapse2 (6%)5 (7%)7 (7%)
Death in remission5 (16%)a4 (6%)a9 (9%)bc

Among patients achieving CR (n = 101), toxicity led to permanent interruption of treatment in 5 cases and 9 additional patients died in CR, during the treatment (6 in C1, 1 in A2, 1 in B2, and 1 in C2), with the main cause of death being infection (Table 3). After a median follow-up of 2.5 years (range = 0.5-6.8 years), 7 relapses (4 in bone marrow, 2 in CNS, and 1 in small bowel) have been documented, with the 4-year DFS probability of 80% (95% confidence interval [CI] = 69%-91%) (Fig. 1A) showing no differences between the 2 cohorts of patients. Thirty patients have died (9 in induction, 1 after withdrawal from therapy, 6 after failure, 9 in remission, and 5 after relapse). Two patients are alive in second CR after rescue chemotherapy. Autologous hematopoietic stem cell transplantation was performed in 1 patient and the remaining patient was waiting for transplantation at the time of this report. The 4-year OS probability of the series was 73% (95% CI = 65%-81%) (Fig. 1B), with only a trend for a lower survival in HIV-infected patients (78% [range = 68%-88%] versus 63% [range = 48%-78%] for HIV-uninfected and HIV-infected patients, respectively, P = .07). Interestingly, no differences were observed in response attainment and in relapse rate in elderly patients, in comparison with those from young patients: 93% CR in young patients versus 100% in older patients, and 5 relapses of 77 young patients who had CR (7%) versus 2 of 24 older patients with CR (8%). The 5-year OS probability of the 91 patients younger than 55 years was 72% ± 10%, versus 76% ± 17% for those aged ≥ 55 years (n = 27).

thumbnail image

Figure 1. (A) Disease-free survival and (B) overall survival are shown of the patients from the series.

Download figure to PowerPoint

Prognostic Factors and Risk Groups Assessment

Because no significant differences were found between HIV-positive and HIV-negative patients in any outcome measure, a joint analysis of prognostic factors was performed. Table 4 shows the results of the multivariate analyses for each of these outcomes. Poor general status influenced the probability of ED, whereas CNS involvement at baseline was associated with a lower probability of CR (Table 5), BM involvement was associated with a shorter DFS, and poor general status and BM involvement were associated with a shorter OS (Table 6). There was no relationship between the CD4 lymphocyte count at the end of the treatment (median = 200 [range = 1-659]/μL) and the DFS and OS. According to the presence of 0, 1, or 2 prognostic factors for survival, 3 groups with different survival were identified with 4-year survival probabilities ranging from 50% to 92% (Fig. 2).

thumbnail image

Figure 2. Risk categories are shown for overall survival according to the prognostic factors.

Download figure to PowerPoint

Table 4. Results of Multivariate Analysis of Prognostic Factors in the Patients of the Series
OutcomeVariableUnfavorable CategoryOR/ HR95% CIP
  1. Abbreviations: BM, bone marrow; CI, confidence interval; CNS, central nervous system; CR, complete response; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OR, odds ratio; OS, overall survival.

Death in inductionECOG≥21.21.1–1.3.001
CRCNS involvementYes9.11.6–50.023
DFSBM involvementYes4.91.5–16.2.008
OSECOG≥22.31.1–5.045
BM involvementYes2.71.2–6.1.014

Treatment-Related Toxicity

Tables 7 and 8 show the toxicity according to the age groups, the cycle of chemotherapy, and HIV infection status. In HIV-infected patients younger than 55 years, hematologic toxicity, mucositis, and infections were significantly more frequent than in HIV-negative patients, whereas no differences in toxicity were observed in patients ≥ 55 years according to HIV infection status. Interestingly, no significant differences were observed in the overall frequency of grade 3 or 4 infections on comparison of the age groups (161 infections in 438 chemotherapy cycles [37%] in young patients versus 37 of 125 [30%] in older patients). Granulocyte colony-stimulating factor was effectively used in the 91% of the cycles, without differences in both age groups.

Table 5. Death in Induction and Complete Response (Univariate Analysis)
VariableCategorynDead, n (%)PnCR, n (%)P
  1. Abbreviations: BM, bone marrow; CNS, central nervous system; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; IPI, International Prognostic Index; LDH, lactate dehydrogenase.

SexMale859 (11%).067571 (95%).99
 Female330 3230 (94%) 
LDH (U/L)Normal100.6161010 (100%).99
 Elevated1068 (8%) 9691 (95%) 
Extranodal involvement 633 (5%).3016059 (98%).085
 =2 sites556 (11%) 4742 (89%) 
CNS involvementNo1049 (9%).3809491 (97%).023
 Yes140 1310 (77%) 
Bulky diseaseNo876 (7%).6967975 (95%).651
 Yes313 (10%) 2826 (93%) 
Age (y) 917 (8%).998371 (95%).334
 =55272 (7%) 2424 (100%) 
ECOG score 620.0016159 (97%).648
 =2559 (16%) 4542 (93%) 
Age-adjusted IPILow/low-intermediate230.2092323 (100%).583
 Intermediate-high/high938 (9%) 8378 (94%) 
BM involvementNo724 (6%).4796763 (94%).99
 Yes465 (11%) 4038 (95%) 
Burkitt leukemiaNo937 (8%).998579 (93%).342
 Yes252 (8%) 2222 (100%) 
Ann Arbor stageNonbulky I–II260.2042626 (100%).332
        
 II (bulky), III–IV929 (10%) 8175 (93%) 
HIV infectionNo804 (5%).1457470 (95%).99
 Yes385 (13%) 3331 (94%) 
Table 6. Disease-Free Survival and Overall Survival (Univariate Analysis)
VariableCategoryn5-y DFS (±95% CI)Pn5-y OS (±95% CI)P
  1. Abbreviations: BM, bone marrow; CI, confidence interval; CNS, central nervous system; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OS, overall survival.

SexMale7182% ± 13%.4118574% ± 10%.815
 Female3079% ± 15% 3370% ± 17% 
LDH (U/L)Normal10No events (100%).17610No events (100%).091
 Elevated7578% ± 12% 10672% ± 9% 
Extranodal involvement 5988% ± 9%.1716381% ± 10%.028
 =2 sites4265% ± 30% 5564% ± 13% 
CNS involvementNo9186% ± 7%.02710476% ± 9%.036
 Yes100% 1450% ± 26% 
Bulky diseaseNo7579% ± 13%.9748773% ± 10%.877
 Yes2685% ± 14% 3173% ± 16% 
Age (y) 7779% ± 12%.6629172% ± 10%.697
 =552487% ± 14% 2776% ± 17% 
ECOG score 5988% ± 9%.2316282% ± 10%.014
 =24272% ± 20% 5564% ± 13% 
Age-adjusted IPILow/low-Intermediate23No events (100%).02523No events (100%).005
 Intermediate-high/high7875% ± 14% 9368% ± 10% 
BM involvementNo6394% ± 6%.0017284% ± 9%.001
 Yes3856% ± 27% 4656% ± 15% 
Burkitt leukemiaNo7983% ± 13%.0989377% ± 9%.179
 Yes2271% ± 20% 2559% ± 21% 
Ann Arbor stageNonbulky I-II26No events (100%).01526No events (100%).002
 II (bulky), III-IV7574% ± 14% 9266% ± 10% 
HIV infectionNo7080% ± 17%.2648078% ± 10%.062
 Yes3177% ± 15% 3863% ± 15% 
Table 7. Grade 3–4 Adverse Events in Patients <55 Years Old According to HIV Infection and Cycle of Chemotherapy
 HIV-Infected (n = 35)Non-HIV-Infected (n = 56)
 Cycles ACycles BCycles CCycles ACycles BCycles C
  • a

    Significant differences between HIV and non-HIV groups in cycles A, B, and C (P = .007, P < .001, and P = .001).

  • b

    Significant differences between HIV and non-HIV groups in cycles B and C (P = .001 and P = .012).

  • c

    Significant differences between HIV and non-HIV groups in cycles A (P = .026).

  • d

    Significant differences between HIV and non-HIV groups in cycles A, B, and C (P < .001, P < .001 and P = .003).

  • e

    Significant differences between HIV and non-HIV groups in cycles A, B, and C (P = .005, P = .001 and P < .001).

  • f

    Significant differences between HIV and non-HIV groups in cycles A (P < .003).

  • Abbreviation: HIV, human immunodeficiency virus.

Number of cycles 5950471049490
Neutropenia a 57/5838/4539/4189/10442/9163/90
Days (median [range])8 [1; 24]5 [1; 19]6 [1; 17]6 [1; 25]5 [1; 15]4 [1; 19]
Thrombocytopenia b 47/5824/4431/4174/10422/9146/89
Days (median [range])6 [1; 20]6 [1; 22]6 [1; 31]4 [1; 25]4 [1; 22]3 [1; 38]
Hepatic c 8/551/4304/1022/901/83
Renal 2/55003/1021/900
Neurologic 2/552/430002/83
Gastrointestinal 1/550001/900
Mucositis d 22/5523/4611/4211/9911/905/82
Tumor lysis syndrome 2/323/55
Infection e 35/5927/4923/4537/10424/9415/87
Death by infection f 6/591/493/451/10402/87
Other 7/553/442/421/10202/83
Table 8. Grade 3-4 Adverse Events in Patients ≥55 Years Old According to HIV Infection and Cycle of Chemotherapy
 HIV-Infected (n = 3)Non-HIV-Infected (n = 24) P
 Cycles ACycles BCycles ACycles BCycles ACycles B
  1. Abbreviation: HIV, human immunodeficiency virus.

Number of cycles 985856  
Neutropenia 9/98/838/5431/51.097.042
Days (median [range])4 [1; 12]4 [1; 7]6 [1; 28]4 [1; 12]
Thrombocytopenia 5/93/826/5415/51.732.690
Days (median [range])2 [2; 3]2 [2; 5]6 [1; 25]4 [1; 19]
Hepatic 002/561/53  
Renal 002/560  
Neurologic 2/9000  
Mucositis 2/92/87/5510/51  
Tumor lysis syndrome 03/23  
Infection 3/9020/5714/51  
Death by infection 1/903/570  
Other 001/561/53  

DISCUSSION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES

This final analysis shows that this age-adapted immunochemotherapeutic schedule is feasible and effective for adult patients with BL, regardless of their HIV infection status, although more hematologic, mucosal, and infectious toxicities were observed in young HIV-infected patients. General status and the presence of CNS and BM involvement, but not age, were the main prognostic factors.

The development of specific chemotherapies by pediatric groups has been the main hallmark in the therapy of BL, with curability indexes of approximately 80% to 90% of cases.15, 16 The adaptation of these schedules to adults has led to an increase in the response rate and survival, ranging from 60% to 70% of cases in some series.17 The addition of rituximab to these specific therapies may represent a step forward in the therapy of BL. Although no randomized trials on the use of rituximab have been published to date, and most of the studies are retrospective and include a limited number of patients, the tolerability and efficacy of specific immunochemotherapy seems to be good, with response rates between 70% and 90% and survival ranging from 70% to 80%.17-21

The high frequency of virologic and immunologic response to HAART and the improvement in supportive therapy have encouraged some groups to treat patients who have HIV-related BL with the same aggressive schedules as those used in patients without immune suppression, with promising results and acceptable tolerability.22-26 Several studies have added rituximab to these schedules, with results comparable to those obtained in HIV-negativepatients.27, 28 However, to our knowledge, no prospective comparison between HIV-positive and HIV-negative patients with BL has been performed.

The BURKIMAB study prospectively evaluated the efficacy and tolerability of the specific immunochemotherapy B-ALL/NHL2002 protocol from the GMALL group,17 with the main modification being the inclusion of patients with HIV-related BLL. This was consistent with our previous studies showing the applicability and equivalent results of specific chemotherapeutic schedules in HIV-positive and HIV-negative BL patients.7, 29 A report of the first 36 patients (17 HIV-negative and 19 HIV-infected) in advanced stages showed the applicability of this schedule in both groups of patients, with similar outcomes.7 In this final analysis, both cohorts of patients had similar baseline characteristics. The CR was similar in both groups, and the frequency of relapses or resistant disease was very low. A matter of concern was the high frequency (9%) of deaths (mainly due to infection), occurring in patients in remission during chemotherapy, being slightly higher in HIV-infected than in HIV-negative patients. Although the relapse rate, DFS, and OS were not significantly different in HIV-positive and HIV-negative patients, grade 3 or 4 myelosuppression and mucositis were more common in young HIV-infected patients, with major infection in half of the cycles. Although CD4 counts were assessed at the end of therapy, the lack of monitoring of HIV viral load and CD4 lymphocyte counts during and sequentially after the treatment could not allow us to determine if there were differences in toxicity and outcomes based on these features. In both HIV-positive and HIV-negative patients aged 55 years or older, the frequency of cytopenias was similar but the duration was lower, with fewer infections and mucositis, probably due to reduced intensity of chemotherapy given to these patients.

The prognostic factors identified in this study (CNS and BM involvement and poor general status) are consistent with those identified in other trials15-28 or in population-based studies30 with the exception of advanced age. We have attributed the lack of poor prognosis in older patients to 2 features. First, the strategy of dose reduction and schedule modification for older patients did not translate into a lower remission rate or increased relapse rate in this population. Second, there was not an excess of toxicity causing treatment-related deaths in older patients in this study. Other trials such as Hyper-CVAD and rituximab showed improvement in disease-related outcomes of de novo BL, particularly for older patients. Future trials should therefore examine whether less-intensive treatment protocols including rituximab can reduce toxicity while maintaining high efficacy. In addition, improved therapeutic strategies are needed for the poorest prognostic group of patients, who have only a 50% probability of survival.

In spite of similar baseline characteristics and results of treatment in HIV-positive and HIV-negative patients, a selection bias cannot be ruled out in this study, especially for the HIV-infected patients, in whom the frequency of BL was lower. However, the high survival rate observed in HIV-related BL also supports the use of intensive protocols with age-adapted immunochemotherapy in these patients. These regimens are feasible, with high CR and very low relapse rates. However, the toxicity is relevant especially with regard to infections and mucositis. The occurrence of deaths during chemotherapy in patients in CR calls for future trials examining protocols with decreased dose-intensity in postremission therapy. The use of risk-adapted therapy, the incorporation of targeted therapies, and the study of minimal residual disease will be useful in the definition of future therapeutic strategies.

FUNDING SOURCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES

Supported in part by the grant RD12-0036-0029 from RTICC Instituto Carlos III, Spain.

REFERENCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. MATERIALS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. FUNDING SOURCES
  8. CONFLICT OF INTEREST DISCLOSURE
  9. REFERENCES
  • 1
    Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012; 379: 1234-1244.
  • 2
    Linch DC. Burkitt lymphoma in adults. Br J Haematol. 2012; 156: 693-703.
  • 3
    Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol. 2012; 156: 234-244.
  • 4
    Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012; 119: 3245-3255.
  • 5
    Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012; 118: 3977-3983.
  • 6
    Oriol A, Ribera JM, Esteve J, et al. PETHEMA Group; Spanish Society of Hematology. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003; 88: 445-453.
  • 7
    Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and non infected patients. Cancer. 2008; 113: 117-125.
  • 8
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361-1392.
  • 9
    Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.
  • 10
    Mitelman F, editor. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
  • 11
    International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994.
  • 12
    Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 13
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977; 35: 1-39.
  • 14
    Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
  • 15
    Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012; 30: 387-393.
  • 16
    Todeschini G, Bonifacio M, Tecchio C, et al. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol. 2012; 87: 22-25.
  • 17
    Hoelzer D, Hiddemann W, Baumann A, et al. High survival rate in adult Burkitt's lymphoma/leukemia and diffuse large B cell lymphoma with mediastinal involvement [Abstract]. Blood. 2007; 110: abstract 518.
  • 18
    Mohamedbhai SG, Sibson K, Marafioti T, et al. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index > 95%. Br J Haematol. 2011; 152: 175-181.
  • 19
    Dujmovic D, Aurer I, Radman I, et al. Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia. Acta Haematol. 2012; 127: 115-117.
  • 20
    Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011; 22: 1859-1864.
  • 21
    Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004; 100: 1438-1448.
  • 22
    Noy A. Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol. 2010; 22: 443-448.
  • 23
    Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS. 2010; 24: 851-856.
  • 24
    Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003; 98: 1196-1205.
  • 25
    Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 1492-1499.
  • 26
    Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007; 110: 2846-2854.
  • 27
    Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
  • 28
    Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012; 2012: 735392.
  • 29
    Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA LAL3/97 study. Haematologica. 2005; 90: 990-992.
  • 30
    Wästerlid T, Jonsson B, Hagberg H, Jerkeman M. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma. 2011; 52: 2090-2096.